{
  "docId": "019de073-8778-764b-accb-e5886cb9e840",
  "docSlug": "a27c0c380497fe380fc0ea99c606f1fe",
  "documentTitle": "Equillium | Results Presentation Deck | 32 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 32,
  "prevPage": 31,
  "nextPage": null,
  "slideType": "key_takeaways",
  "function": "state_next_steps",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8778-764b-accb-e5886cb9e840/32",
  "deckHref": "/decks/019de073-8778-764b-accb-e5886cb9e840",
  "deckJsonHref": "/decks/019de073-8778-764b-accb-e5886cb9e840.json",
  "deckAnchorHref": "/decks/019de073-8778-764b-accb-e5886cb9e840#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.9,
        "x": 0.05,
        "y": 0.26
      },
      "kind": "list",
      "text": "Itolizumab continues to demonstrate a favorable safety and tolerability profile at 1.6 mg/kg dose through six months of treatment\nEmerging product profile suggests differentiation in early, rapid, and deep responses in highly proteinuric patients\nAdds to our conviction in the clinical activity of itolizumab and the potential to be an impactful therapy for patients with severe immuno-inflammatory diseases",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e0629a2-c21f-44e8-ac22-9bb53d064ae2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "list",
      "text": "Continue enrollment in the EQUALISE study – topline data anticipated mid-2023\nContinue analysis of serologies and biomarkers such as soluble ALCAM to response rates\nPrepare for later stage development that can support product registration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d25a691d-9ecd-4af8-9af5-c76fd9c8340b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.038,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "Based on compelling data and KOL feedback, Equillium plans to:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "681da08b-3df4-4a18-b63c-a704fbf7e274",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.55,
        "x": 0.038,
        "y": 0.215
      },
      "kind": "paragraph",
      "text": "Key learnings from EQUALISE Type B lupus nephritis interim data:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fade2a13-2b46-4044-b919-b7486ace3466",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.105,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Based on interim data from 2 Sep 2022 – subject to change; Abbreviations: ALCAM activated leukocyte cell adhesion molecule; KOL key opinion leader",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f92402b-67b9-4694-983d-2112c9af8191",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.181,
        "x": 0.036,
        "y": 0.085
      },
      "kind": "title",
      "text": "Next Steps",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4c8a617-5eca-4a64-800b-382d6019e793",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}